Bioforce Nanosciences Changes Auditors

TL;DR

Bioforce Nanosciences just switched auditors from RBSK Partners LLP to Citrin Cooperman & Co., LLP.

AI Summary

Bioforce Nanosciences Holdings, Inc. filed an 8-K on May 7, 2024, to report a change in its certifying accountant. The company previously engaged with RBSK Partners LLP, but has now appointed Citrin Cooperman & Co., LLP as its new independent registered public accounting firm. This change was effective immediately.

Why It Matters

A change in auditors can sometimes signal underlying issues or a desire for a fresh perspective on financial reporting.

Risk Assessment

Risk Level: medium — A change in auditors, especially without explicit reasons provided in the filing, can introduce uncertainty about the company's financial reporting and internal controls.

Key Players & Entities

• BIOFORCE NANOSCIENCES HOLDINGS, INC. (company) — Registrant
• RBSK Partners LLP (company) — Former Certifying Accountant
• Citrin Cooperman & Co., LLP (company) — New Certifying Accountant
• May 7, 2024 (date) — Filing Date

FAQ

Filing Documents

• bfnh0705248k.htm (8-K) — 21KB
• 0001091818-24-000056.txt ( ) — 184KB
• bfnh-20240507.xsd (EX-101.SCH) — 3KB
• bfnh-20240507_lab.xml (EX-101.LAB) — 33KB
• bfnh-20240507_pre.xml (EX-101.PRE) — 22KB
• bfnh0705248k_htm.xml (XML) — 3KB

01

Item 4.01 Change in Registrant's Certifying Accountant. Effective May 7, 2024, BioForce NanoSciences Holdings, Inc. (the "Company) replaced BF Borgers CPA PC ("BF Borgers") as its independent registered public accounting firm. The Company has retained Michael Gillespie & Associates, PLLC as its new auditing firm. BF Borgers' audit reports on the Company's consolidated financial statements as of and for the fiscal years ended December 31, 2023, and December 31, 2022 did not contain an adverse opinion or a disclaimer of opinion and were not qualified or modified as to audit scope or accounting principles. During the fiscal years ended December 31, 2023 and 2022, and the subsequent interim period through the date of this report, there were no disagreements, as that term is defined in Item 304(a)(1)(iv) of Regulation S-K, between the Company and BF Borgers on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to BF Borgers' satisfaction, would have caused BF Borgers to make reference to such disagreements in its audit reports. During the fiscal years ended December 31, 2023 and 2022, and the subsequent interim period through the date of this report, there were no reportable events within the meaning of Item 304(a)(1)(v) of Regulation S-K.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). -2-

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: May 7, 2024 BIOFORCE NANOSCIENCES HOLDINGS, INC. By: /s/ Richard Kaiser Richard Kaiser – Chief Financial Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR